Previous studies have examined the possibility of using adenovirus-based intracoronary infusion of the human angiogenic FGF-4 gene (Ad5FGF-4) to improve myocardial perfusion and regional left ...

Using a mathematical modeling approach, scientists have found that certain parameters of tumor growth in mice can predict the effectiveness of drugs that block formation of tumor-nourishing blood ...

In 2018, lung cancer caused 1.8 million cancer deaths worldwide. It is the most common type of cancer, with non-small cell lung cancers (NSCLCs) accounting for 85% of lung cancers. Most recent lung ...

Primary pulmonary nuclear protein of the testis (NUT) midline carcinoma (NMC) is an extremely rare, highly aggressive thoracic malignancy that ...

Most tumors release various signaling molecules to support their incessant growth, invasion, and metastasis. Some of these molecules, known as tumor angiogenic factors (TAF), are able to stimulate the ...

The arrival of oral tyrosine kinase inhibitors (TKIs) radically changed the treatment paradigm in EGFR-mutated advanced non-small cell lung cancer (NSCLC), and this was followed by development of next ...

Researchers with The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) have identified a new molecular drug ...

Collateral Therapeutics Inc.'s angiogenic gene therapy, Ad5-FGF4, appeared safe and well tolerated, not to mention efficacious, in treatment of patients with stable exertional angina due to coronary ...

JERUSALEM--(BUSINESS WIRE)--Tiltan Pharma Ltd. today announced that it has commenced a Phase 2 clinical trial of its anti-angiogenic product TL-118 for the treatment of pancreatic cancer. Following an ...